FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
CAMBRIDGE, Mass., Feb. 24, 2016 -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will present at the Canaccord Genuity Musculoskeletal Conference in Orlando, FL on Tuesday, March 1, 2016; Vericel CFO Gerard Michel will present a corporate update at 3:30PM EST with a live webcast at http://wsw.com/webcast/canaccord22/vcel.
About Vericel Corporation
Vericel Corporation is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the U.S.: Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Vericel is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company’s website at www.vcel.com.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922
